

Peter M A Calverley

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9420366/peter-m-a-calverley-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148
papers

22,653
citations

53
h-index

150
g-index

167
ext. papers

25,808
ext. citations

11.6
avg, IF

6.43
L-index

#	Paper	IF	Citations
148	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 532-55	10.2	5242
147	Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2007 , 356, 775-89	59.2	2457
146	Susceptibility to exacerbation in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1128-38	59.2	1840
145	Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2003 , 361, 449-56	40	961
144	Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , 2010 , 11, 122	7.3	752
143	Changes in forced expiratory volume in 1 second over time in COPD. <i>New England Journal of Medicine</i> , 2011 , 365, 1184-92	59.2	654
142	The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 19-26	10.2	636
141	Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. <i>Lancet, The</i> , 2009 , 374, 685-94	40	591
140	Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 332-8	10.2	566
139	Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. <i>PLoS ONE</i> , 2012 , 7, e37483	3.7	521
138	Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. <i>Lancet, The</i> , 2009 , 374, 695-703	40	469
137	Withdrawal of inhaled glucocorticoids and exacerbations of COPD. <i>New England Journal of Medicine</i> , 2014 , 371, 1285-94	59.2	407
136	Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1065-72	10.2	288
135	Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. <i>Lancet Respiratory Medicine, the</i> , 2016 , 4, 390-8	35.1	271
134	Tiotropium Respimat inhaler and the risk of death in COPD. <i>New England Journal of Medicine</i> , 2013 , 369, 1491-501	59.2	270
133	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1817-26	40	263
132	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	256

131	Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 154-61	10.2	256
130	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 210-23	35.1	249
129	Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2015 , 385, 857-66	40	248
128	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , 2009 , 10, 59	7.3	234
127	Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 382-6	10.2	206
126	Prevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD Health study. <i>Chest</i> , 2009 , 136, 1456-1465	5.3	202
125	Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. <i>Respiratory Research</i> , 2011 , 12, 18	7.3	194
124	Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. <i>Journal of the American Medical Directors Association</i> , 2012 , 13, 291-7	5.9	167
123	Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , 2016 , 47, 1374-82	13.6	159
122	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. <i>Lancet, The</i> , 2009 , 374, 712-9	40	155
121	Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2010 , 104, 849-57	4.6	148
120	Cardiovascular events in patients with COPD: TORCH study results. <i>Thorax</i> , 2010 , 65, 719-25	7.3	142
119	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013 , 42, 636-46	13.6	139
118	Reported pneumonia in patients with COPD: findings from the INSPIRE study. <i>Chest</i> , 2011 , 139, 505-512	5.3	130
117	Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 1510-6	10.2	129
116	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012 , 67, 701-8	7.3	122
115	Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 317-22	10.2	122
114	Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 1022-30	10.2	117

113	Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 337-344	35.1	116
112	Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. <i>European Respiratory Journal</i> , 2014 , 44, 789-91	13.6	115
111	Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014 , 69, 666-72	7.3	102
110	Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 27-34	4.7	98
109	Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. <i>Respiratory Medicine</i> , 2011 , 105, 1069-78	4.6	95
108	Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 303-12	4.7	93
107	Fluticasone furoate/vilanterol (100/25; 200/25 μ) improves lung function in COPD: a randomised trial. <i>Respiratory Medicine</i> , 2013 , 107, 550-9	4.6	92
106	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	89
105	Roflumilast: a review of its use in the treatment of COPD. <i>International Journal of COPD</i> , 2016 , 11, 81-90	3	89
104	Withdrawal from treatment as an outcome in the ISOLDE study of COPD. <i>Chest</i> , 2003 , 124, 1350-6	5.3	86
103	Efficacy of roflumilast in the COPD frequent exacerbator phenotype. <i>Chest</i> , 2013 , 143, 1302-1311	5.3	84
102	Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1219-1221	10.2	81
101	Maintenance rehabilitation for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2019 ,	5.2	78
100	Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. <i>Chest</i> , 2013 , 144, 758-765	3.5	72
99	Telemonitoring in Chronic Obstructive Pulmonary Disease (CHROMED). A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 620-628	10.2	70
98	Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. <i>Respiratory Medicine</i> , 2004 , 98, 1045-50	4.6	67
97	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , 2013 , 41, 1017-22	13.6	65
96	Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. <i>Chest</i> , 2014 , 145, 1286-1297	5.3	61

95	Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. <i>Lancet Respiratory Medicine, the</i> , 2013 , 1, 564-73	35.1	50
94	Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	48
93	What have we learned from large drug treatment trials in COPD?. <i>Lancet, The</i> , 2007 , 370, 774-85	40	47
92	Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. <i>Thorax</i> , 2015 , 70, 930-8	7.3	45
91	A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017 , 18, 153	7.3	45
90	The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. <i>Respiratory Research</i> , 2013 , 14, 40	7.3	44
89	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1268-1278	10.2	43
88	Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 712-8	5.9	41
87	Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 164	3.5	39
86	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 881-888	10.2	38
85	A score to predict short-term risk of COPD exacerbations (SCOPEX). <i>International Journal of COPD</i> , 2015 , 10, 201-9	3	38
84	Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma. <i>Chest</i> , 2012 , 141, 616-624	5.3	38
83	Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. <i>Respiratory Medicine</i> , 2014 , 108, 593-9	4.6	36
82	One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2008 , 9, 73	7.3	36
81	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 47-55	10.2	34
80	Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2006 , 3, 233-42	2	33
79	Minimal clinically important difference--exacerbations of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005 , 2, 143-8	2	33
78	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1126-1137	15.1	31

77	The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008 , 5, 147-52	2	27
76	A new perspective on optimal care for patients with COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011 , 20, 205-9		26
75	Development of a population-based screening questionnaire for COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005 , 2, 225-32	2	26
74	Effect of roflumilast in patients with severe COPD and a history of hospitalisation. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	24
73	Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data. <i>Respiratory Medicine</i> , 2008 , 102, 1615-24	4.6	24
72	Triple Therapy in COPD: What We Know and What We Don't. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017 , 14, 648-662	2	23
71	Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. <i>International Journal of COPD</i> , 2012 , 7, 375-82	3	23
70	Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2007 , 4, 177-83	2	22
69	Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2004 , 1, 121-4		22
68	Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. <i>Respiratory Medicine</i> , 2014 , 108, 366-75	4.6	21
67	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , 2017 , 131, 27-34	4.6	21
66	Treatments for COPD. <i>Respiratory Medicine</i> , 2005 , 99 Suppl B, S28-40	4.6	21
65	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016 , 119, 87-95	4.6	21
64	The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. <i>Respiratory Medicine</i> , 2007 , 101, 746-53	4.6	20
63	Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014 , 1, 166-184	2.7	19
62	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000431	5.6	18
61	The Association Between Heroin Inhalation and Early Onset Emphysema. <i>Chest</i> , 2015 , 148, 1156-1163	5.3	18
60	The role of corticosteroids in chronic obstructive pulmonary disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005 , 26, 235-45	3.9	18

59	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018 , 39, 3128-3134	9.5	17
58	Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. <i>European Respiratory Journal</i> , 2016 , 47, 651-4	13.6	16
57	The Tiotropium Safety and Performance in Respimat [®] (TIOSPIR [®]) Trial: Spirometry Outcomes. <i>Respiratory Research</i> , 2015 , 16, 107	7.3	16
56	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020 , 158, 952-964	5.3	15
55	The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 24	2.8	15
54	Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. <i>Respiratory Medicine</i> , 2018 , 143, 67-73	4.6	15
53	Pathological networking: a new approach to understanding COPD. <i>Postgraduate Medical Journal</i> , 2007 , 62, 733-8	2	14
52	Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. <i>Respiratory Research</i> , 2020 , 21, 240	7.3	14
51	Are inhaled corticosteroids systemic therapy for chronic obstructive pulmonary disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 721-2	10.2	13
50	The severity of airways obstruction as a determinant of treatment response in COPD. <i>International Journal of COPD</i> , 2006 , 1, 209-18	3	12
49	A rational approach to single, dual and triple therapy in COPD. <i>Respirology</i> , 2016 , 21, 581-9	3.6	12
48	Large trials, new knowledge: the changing face of COPD management. <i>European Respiratory Journal</i> , 2015 , 45, 1692-703	13.6	11
47	FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. <i>International Journal of COPD</i> , 2020 , 15, 1135-1142	3	11
46	Effect of corticosteroids on exacerbations of asthma and chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2004 , 1, 161-6		11
45	Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. <i>Respiratory Medicine</i> , 2019 , 147, 37-43	4.6	11
44	Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. <i>Npj Primary Care Respiratory Medicine</i> , 2015 , 25, 15067	3.2	10
43	Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. <i>International Journal of COPD</i> , 2014 , 9, 657-73	3	10
42	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 689-698	10.2	10

41	The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV/FVC Ratio in Tiotropium Safety and Performance in RespiMat Participants. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 200-208	4.7	9
40	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 145	3.5	9
39	A PEACE-ful solution to COPD exacerbations?. <i>Lancet, The</i> , 2008 , 371, 1975-6	4.0	8
38	Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. <i>Respiratory Research</i> , 2016 , 17, 27	7.3	7
37	Current drug treatment, chronic and acute. <i>Clinics in Chest Medicine</i> , 2014 , 35, 177-89	5.3	7
36	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	7
35	New treatments for COPD: many miles still to go. <i>Lancet Respiratory Medicine, the</i> , 2014 , 2, 6-7	35.1	6
34	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	6
33	The Association Between Dietary Intake and Phenotypical Characteristics of COPD in the ECLIPSE Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014 , 1, 115-124	2.7	6
32	A Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1125-1127	10.2	5
31	New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 523-42	3.9	5
30	The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials. <i>International Journal of COPD</i> , 2017 , 12, 1457-1468	3	5
29	COPD therapy: if two is good, is three better?. <i>Lancet, The</i> , 2016 , 388, 937-8	4.0	4
28	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO/DYNAGITO Trials. <i>Advances in Therapy</i> , 2020 , 37, 4266-4279	4.1	4
27	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , 2019 , 5,	3.5	3
26	Long-Acting β Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1641-1644	10.2	3
25	How to write research papers and grants: 2011 Asian Pacific Society for Respiriology Annual Scientific Meeting Postgraduate Session. <i>Respirology</i> , 2012 , 17, 792-801	3.6	3
24	Side-effects of roflumilast [AuthorsTreply. <i>Lancet, The</i> , 2012 , 379, 711-712	4.0	3

23	A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.. <i>International Journal of COPD</i> , 2022 , 17, 545-558	3	3
22	Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	2
21	The Tiotropium Safety and Performance in Respimat (TIOSPIR) trial: Bronchodilator efficacy in a spirometry substudy. <i>Chest</i> , 2013 , 144, 1027A	5.3	2
20	UPLIFTing care for chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2009 , 374, 1129-30	4.0	2
19	Budesonide and risk of pneumonia [AuthorsTreply. <i>Lancet, The</i> , 2009 , 374, 2051-2052	4.0	2
18	Maintenance rehabilitation for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2010 ,	5.2	2
17	Today's management of chronic obstructive pulmonary disease. <i>The Prescriber</i> , 2007 , 18, 50-63	0.4	2
16	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021 , 7,	3.5	2
15	Tiotropium Respimat() Versus HandiHaler(): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials. <i>Advances in Therapy</i> , 2016 , 33, 786-93	4.1	2
14	Regional differences in rate of FEV decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	1
13	Response. <i>Chest</i> , 2014 , 145, 428	5.3	1
12	Fluticasone furoate and vilanterol for COPD - authorsTreply. <i>Lancet Respiratory Medicine,the</i> , 2013 , 1, e21-2	35.1	1
11	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , 2021 ,	4.7	1
10	Overnight variation in tidal expiratory flow limitation in COPD patients and its correction: an observational study.. <i>Respiratory Research</i> , 2021 , 22, 319	7.3	1
9	Predicting loss of lung function in healthy people. <i>Lancet Respiratory Medicine,the</i> , 2015 , 3, 590-1	35.1	
8	Better lungs for better legs: novel bronchodilator effects in COPD. <i>Thorax</i> , 2010 , 65, 573-5	7.3	
7	Treatment options in chronic obstructive pulmonary disease. <i>The Prescriber</i> , 2010 , 21, 14-24	0.4	
6	Management of Patients with COPD: A Comparison of the INSPIRE and TORCH Studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 106-107	10.2	

5 Cough in Chronic Obstructive Pulmonary Disease 125-135

4 Pharmacological Therapy: Inhaled Corticosteroids 2011, 115-127

3 Pharmacological Treatment: an Update 2014, 311-321

2 COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 2020, 17, 477-484 2

1 COPD in the time of COVID-19. *EClinicalMedicine*, 2021, 34, 100832 11.3